This randomized, multicenter, double-blind, placebo-controlled study will evaluate the
efficacy and safety of onartuzumab (MetMAb) in combination with Tarceva (erlotinib) in
participants with incurable non-small cell lung cancer identified to be Met
diagnostic-positive. Participants will be randomized to receive either onartuzumab (MetMAb)
or placebo in combination with erlotinib. Anticipated time on study treatment is until
disease progression or unacceptable toxicity occurs.